LABP Landos Biopharma, Inc.

Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel oral therapeutics for patients with autoimmune diseases. Our pipeline, which currently contains seven preclinical and clinical product candidates, leverages our LANCE precision medicine platform to optimally identify novel immunometabolic targets and address a wide range of disease indications.

$15.47  +0.20 (1.31%)
As of 09/17/2021 15:59:59 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  02/04/2021
Outstanding shares:  40,117,598
Average volume:  45,875
Market cap:   $612,595,721
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    515069102
ISIN:        US5150691021
Sedol:      BMVHFM0
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy